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Abstract
A variety of 2-amino-3-arylpropan-1-ols, anti-2-amino-3-aryl-3-methoxypropan-1-ols and anti-2-amino-1-arylpropan-1,3-diols
were prepared selectively through elaboration of trans-4-aryl-3-chloro-β-lactams. In addition, a number of 2-(azidomethyl)-
aziridines was converted into novel 2-[(1,2,3-triazol-1-yl)methyl]aziridines by Cu(I)-catalyzed azide-alkyne cycloaddition, fol-
lowed by microwave-assisted, regioselective ring opening by dialkylamine towards 1-(2,3-diaminopropyl)-1,2,3-triazoles. Although
most of these compounds exhibited weak antiplasmodial activity, six representatives showed moderate antiplasmodial activity
against both a chloroquine-sensitive and a chloroquine-resistant strain of Plasmodium falciparum with IC50-values of ≤25 μM.
Introduction
Malaria remains a major issue in health control, especially in
developing countries. This disease affects 40% of the global
population, causing an annual mortality of one million people
[1]. Despite recent advances in the development of a vaccine
against malaria, chemotherapy remains the most viable alter-
native towards treatment of the disease [2]. In light of the rapid
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Figure 1: Functionalized aminopropanes as potential antimalarial agents.
emergence of multiple drug resistance to clinically established
antimalarial drugs, however, there is a compelling need to intro-
duce new chemicals that can overcome this resistance. In 2007,
nitrogen-analogues of glycerol, which have a long-standing
tradition in medicine as β-blockers, were introduced as a novel
class of antimalarials [3]. Prior to this, the well known
β-blocker propranolol was shown to inhibit infection of erythro-
cytes by P. falciparum, as well as to reduce the parasitaemia of
P. berghei infections in vivo [4,5]. In light of the biological
potential of these compounds, continuous efforts have been
devoted to the preparation of structurally diverse analogues
bearing a functionalized propane skeleton [6-8]. In that respect,
we have been engaged in the stereoselective synthesis of syn-2-
alkoxy-3-amino-3-arylpropan-1-ols 1 by reductive ring opening
of the corresponding β-lactams, which were shown to be of
great importance as novel antiplasmodial agents (Figure 1) [6].
More recently, we reported 1,2,3-triaminopropanes 2 as a new
class of antimalarial compounds (Figure 1), prepared through
microwave-assisted, regioselective ring opening of the corre-
sponding 2-(aminomethyl)aziridines by diethylamine [8].
Nonetheless, a number of challenges with regard to
structure–activity relationship studies of functionalized amino-
propanes remain unaddressed, especially concerning the
screening of structural analogues of aminopropanes 1 and 2.
In the present paper, the synthesis of racemic anti-2-amino-
propan-1-ols 3 is described as a variant of the syn-3-amino-
propan-1-ols 1 synthesis (regio- and stereoisomerism with
respect to the relative position of the amino group NHR2 and
the oxygen substituent OR3, Figure 1), by applying a different
synthetic route. Furthermore, a new synthetic approach is
disclosed towards racemic aminopropanes 4 bearing a 1,2,3-
triazole moiety, as structural analogues of the previously
reported 1,2,4-triazoles 2 (Figure 1). Both classes of functional-
ized aminopropanes 3 and 4 were tested for their antiplas-
modial activity.
Results and Discussion
Synthesis
Within azaheterocyclic chemistry, aziridines [9-17] and
β-lactams [18-27] are extraordinary classes of strained com-
pounds with diverse synthetic and biological applications. In
previous works, we have elaborated the synthetic potential of
3-chloroazetidin-2-ones with a focus on stereoselectivity, thus
providing convenient entries into, e.g., aziridines, azetidines and
β-aminoalcohols [28-31]. In continuation of our interest in the
use of functionalized β-lactams as synthons for further elabo-
ration, racemic trans-4-aryl-3-chloro-β-lactams 5 were prepared
by treatment of N-(arylmethylidene)alkylamines (synthesized in
high yields through condensation of the corresponding
benzaldehydes with the appropriate primary amines in CH2Cl2
in the presence of anhydrous MgSO4) with 1.5 equiv of
chloroacetyl chloride and 3 equiv of 2,6-lutidine in benzene
according to a literature protocol [30]. Subsequently, β-lactams
5 were subjected to LiAlH4-mediated reductive ring opening,
furnishing either 2-aminopropan-1-ols 6a–c, by using two molar
equiv of LiAlH4 in Et2O under reflux for 20–80 h, or trans-2-
aryl-3-(hydroxymethyl)aziridines 7a–h by applying milder
reactions conditions (i.e., one molar equiv of LiAlH4 in Et2O at
room temperature for 5–8 h) (Scheme 1) [30].
As aziridines are known to be versatile synthetic intermediates
for the preparation of a variety of ring-opened and ring-
expanded amines, the aziridines 7 were deployed as substrates
for the stereoselective synthesis of functionalized amino-
propanols. In accordance with a literature approach [30], the
nonactivated trans-2-aryl-3-(hydroxymethyl)aziridines 7 were
regio- and stereoselectively converted into anti-2-amino-3-aryl-
3-methoxypropan-1-ols 8a–e through heating in methanol under
reflux (Scheme 1). Furthermore, in order to provide access to
the class of 2-aminopropan-1,3-diols, aziridines 7 were evalu-
ated for the first time as substrates for a water-induced aziri-
dine ring opening in an acidic medium. Thus, treatment of
trans-2-aryl-3-(hydroxymethyl)aziridines 7 with one equiv of
para-toluenesulfonic acid in a H2O/THF (1/1) solvent system
[32] furnished novel anti-2-amino-1-arylpropan-1,3-diols 9a–d
in good yields after 3 h at 40 °C, again in a regio- and stereo-
specific way (Scheme 1). The observed regio- and stereoselec-
tivity in aminopropanols 8 and 9 can be rationalized by consid-
ering the ring opening of the aziridine moiety at C2 due to
benzylic stabilization of the developing carbenium ion in an
SN2 fashion [30].
Beilstein J. Org. Chem. 2011, 7, 1745–1752.
1747
Scheme 1: Synthesis of aminopropanols 6, 8 and 9.
Scheme 2: Synthesis of syn-aminopropan-1,3-diols 12.
As the use of imines bearing a N-tert-butyl group in combina-
tion with a substituent in the ortho-position of the aromatic ring
is known to afford the corresponding cis-4-aryl-3-chloro-
azetidin-2-ones as the major stereoisomers after condensation
with chloroketene in benzene [30], racemic cis-3-chloro-β-
lactams 10a,b were prepared and converted into cis-2-aryl-3-
(hydroxymethyl)aziridines 11a,b upon treatment with two
molar equiv of LiAlH4 in Et2O under reflux for 15 h
(Scheme 2). Next, the aziridines 11, which have previously
been shown to be unreactive towards LiAlH4 and methanol and
thus unable to undergo ring opening [30], were used as
substrates for a water-induced ring opening through initial
protonation of the aziridine ring with p-TsOH. Although more
drastic reaction conditions were required compared to the ring
opening of trans-2-aryl-3-(hydroxymethyl)aziridines 7 (3 equiv
p-TsOH, Δ, 30 h instead of 1 equiv p-TsOH, 40 °C, 3 h), novel
syn-aminopropanols 12a,b were obtained in a selective and con-
venient way (Scheme 2, yields after purification), providing the
first example of the ring opening of this type of aziridines. Also
in this case, the observed regio- and stereoselectivity in the for-
mation of aminopropanols 12 can be rationalized by consid-
ering the ring opening of the aziridine moiety at C2 due to
benzylic stabilization of the developing carbenium ion in an
SN2 fashion [30]. The formation of the other regio- and
stereoisomers was excluded based on detailed spectroscopic
analysis.
It should be noted that both diastereomeric antipodes of the
class of 1-aryl-2-aminopropan-1,3-diols, i.e., anti- and syn-
aminopropanols 9 and 12, can now be prepared selectively
through choice of the appropriate imine for the Staudinger syn-
thesis of the starting β-lactams.
Given the recently disclosed antiplasmodial activities of a
number of 2,3-diamino-1-(1,2,4-triazol-1-yl)propanes [8], the
second objective of this work was the preparation of new
analogues bearing a 1,2,3-triazole moiety instead. A powerful
methodology towards the synthesis of functionalized 1,2,3-tri-
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Scheme 3: Synthesis of 2-[(1,2,3-triazol-1-yl)methyl]aziridines 15 and their transformation into 1,2,3-triaminopropanes 16.
azoles involves the Cu(I)-catalyzed azide-alkyne Huisgen
cycloaddition (CuAAC) [33], which has gained major interest
from the synthetic community due to its high efficiency and
selectivity. Eligible substrates to perform “click chemistry” [34]
incorporate an azide group and an aziridine ring in their struc-
ture, for example in 2-(azidomethyl)aziridines, thus providing a
direct access to 2-[(1,2,3-triazol-1-yl)methyl]aziridines through
Cu-catalyzed reaction with alkynes [35].
In this work, nonactivated N-(arylmethyl)aziridines were
selected as substrates, as previous research had revealed the
importance of N-benzyl, N-chlorobenzyl and N-methoxybenzyl
groups in functionalized aminopropanes with regard to their
antiplasmodial activity [6,8]. Thus, a number of racemic
2-(azidomethyl)aziridines 14 was prepared by reaction of
sodium azide with 2-(bromomethyl)aziridines 13 [36-38],
employing the electrophilicity of the latter as a convenient
handle for their connection to other moieties. In this way, novel
2-(azidomethyl)aziridines 14a–e were prepared in good yields
by treatment of bromides 13 with two equiv of sodium azide in
DMSO at 80 °C for 16 h (CAUTION) (Scheme 3). Subse-
quently, a CuI-catalyzed 1,3-cycloaddition of N-(arylmethyl)-
aziridine azides 14 was evaluated for the first time by utilizing
one equiv of an arylacetylene in CH3CN under reflux for 16 h,
furnishing a direct entry towards new 2-[(1,2,3-triazol-1-
yl)methyl]aziridines 15a–f in a highly efficient and selective
way (Scheme 3).
The final step comprised ring opening of the aziridine moiety in
compounds 15 by diethylamine to afford functionalized amino-
propanes as potential antimalarial agents. With the intention to
introduce a diethylamino group, a microwave-promoted ring
opening of analogous aziridines by diethylamine with the aid of
the Et2NH·HCl/Et2NH system was employed [8]. In this way,
protonation of the aziridine ring provides a highly electrophilic
aziridinium intermediate, which is prone to undergo nucle-
ophilic ring opening. In order to drive the reaction to comple-
tion, and to avoid competition between chloride- and diethyl-
amine-induced ring opening, a large excess of Et2NH·HCl
(20 equiv) and an additional amount of diethylamine (10 equiv)
was used. Thus, heating of the aziridines 15 at 140 °C in
CH3CN under microwave irradiation resulted in full and selec-
tive conversion to the desired new triaminopropanes 16a–e after
2 h (Scheme 3), which were purified by column chromatog-
raphy (SiO2) in order to obtain analytically pure samples.
Furthermore, in addition to the use of diethylamine, the intro-
duction of a dimethylamino group was considered in order to
compare the contribution of this moiety to the potential
antiplasmodial activity with that of a diethylamino group. This
objective was achieved by treatment of aziridines 15 with
20 equiv of Me2NH·HCl in CH3CN at 140 °C for 2 h under
microwave irradiation, resulting in dimethylaminopropanes
16f,g in good yields (Scheme 3). This result showed that this
microwave-assisted methodology for the ring opening of nonac-
tivated aziridines can be further extended towards the use of
other secondary amines. In order to introduce structural diver-
sity within these molecules, different substituent patterns at the
aromatic rings (R1, R2) in aminopropanes 16a–g were realized
as well.
In view of the biological potential of aminopropanes in general,
compounds 6, 8, 9, 12 and 16 were subsequently screened for
their antiplasmodial activity.
In addition, aziridines 14 and 15 were tested against the malaria
parasite Plasmodium falciparum, too.
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Table 1: IC50-values of compounds 6, 8, 9, 12, 14, 15 and 16 tested for in vitro antiplasmodial activity and cytotoxicity.
Compound R1 R2 R3 D10:
IC50 (μM)
Dd2:
IC50 (μM)
CHO:
IC50 (μM)
RIa SIb
6a 4-Cl Bn – 12.58 10.88 137.90 0.9 11
6b 4-OMe iBu – 281.58 ND ND ND ND
6c 2-F n-Pr – 217.34 ND ND ND ND
8a H iPr – 369.70 ND ND ND ND
8b H Bn – 143.79 ND ND ND ND
8c 4-Cl Bn – 198.56 ND ND ND ND
8d 4-OMe iBu – 38.56 25.69 >530 0.7 ND
8e 2-F n-Pr – 38.54 21.92 >530 0.6 ND
9a 4-Cl Bn – 25.22 8.47 >530 0.3 ND
9b 2-Cl Bn – 21.18 13.57 >530 0.6 ND
9c 4-Me Bn – 129.86 ND ND ND ND
9d H 4-ClBn – 80.68 ND ND ND ND
12a OMe – – 98.68 ND ND ND ND
12b F – – 60.46 ND ND ND ND
14a H – – 230.40 466.81 >530 2 ND
14b 4-Cl – – 100.82 ND ND ND ND
14c 4-OMe – – 160.50 ND ND ND ND
14d 2-Cl – – 93.68 ND ND ND ND
14e 3-Cl – – 179.86 ND ND ND ND
15a H H – 34.44 106.97 >530 3.1 ND
15b 4-Cl H – 41.32 ND ND ND ND
15c 4-OMe H – 25.69 55.65 >530 2.2 ND
15d H Me – 20.43 20.99 >530 1 ND
15e H OMe – 40.54 ND ND ND ND
15f 2-Cl H – 32.33 25.00 >530 0.8 ND
16a H H Et 22.09 231.47 >530 10.5 ND
16b 4-Cl H Et 25.86 176.40 >530 6.8 ND
16c 4-OMe H Et 139.61 ND ND ND ND
16d H Me Et 32.55 ND ND ND ND
16e H OMe Et 171.37 ND ND ND ND
16f 2-Cl H Me 11.33 13.03 181.83 1.2 16.1
16g H H Me 69.58 ND ND ND ND
CQ 19.14 ng/mL
(n = 6)
75.56 ng/mL
(n = 5)
3.9
Emetine 0.27
(n = 6)
aRI (Resistance Index) = IC50 Dd2/IC50 D10; bSI (Selectivity Index) = IC50 CHO/IC50 D10; ND = not determined; n = number of data sets averaged.
The more hydrophobic samples were added to the parasites as a suspension, meaning that for these samples the reported IC50-value might be an
underestimation of the activity.
Biological evaluation
At first, compounds 6a–c, 8a–e, 9a–d, 12a,b, 14a–e, 15a–f and
16a–g were screened for in vitro antiplasmodial activity. All
samples were tested in triplicate on one occasion against a
chloroquine-sensitive (CQS) strain of P. falciparum (D10).
Those samples showing antiplasmodial activity were then tested
in triplicate on one occasion against a chloroquine-resistant
(CQR) strain of P. falciparum (Dd2) and screened for in vitro
cytotoxicity against a Chinese hamster ovary (CHO) cell-line,
in triplicate on one occasion. The antiplasmodial and cytotoxic-
ity assays were performed as described previously [8,39,40].
The results from the biological study are summarized in
Table 1. Although most of these compounds were shown to
possess weak or no antiplasmodial activity, eight of them (i.e.,
compounds 6a, 9a,b, 15c,d, 16a,b,f) were identified as poten-
tially interesting for further study with IC50-values of ≤25 μM.
Moreover, these compounds, with the exception of triamino-
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propanes 16a,b, also proved to be active against a chloroquine-
resistant strain of P. falciparum (Dd2). In addition, the in vitro
cytotoxicity results showed that only compounds 6a and 16f
have lower selectivity with SI’s of 11 and 16, respectively,
whereas the other compounds did not show cytotoxicity at the
concentrations tested.
Although the aziridine moiety was initially only considered as a
synthetically useful entity, two 2-[(1,2,3-triazol-1-yl)methyl]-
aziridines (15c and 15d) were also found to exhibit weak
antiplasmodial activity. On the other hand, the aminopropane
unit has again proven its value as a template for the preparation
of novel antimalarial agents, as a variety of structurally different
aminopropanes were demonstrated to exhibit weak to moderate
antiplasmodial activity. In particular, antiplasmodial assays
against a chloroquine-sensitive strain of P. falciparum (D10)
showed activity for 2-aminopropan-1-ol 6a, 2-aminopropan-
1,3-diols 9a,b and triaminopropanes 16a,b,f with IC50-values
between 11.3 and 25.9 μM. Moreover, screening against a
chloroquine-resistant strain of P. falciparum (Dd2) revealed
antiplasmodial activity for 2-aminopropan-1-ol 6a, 2-amino-
propan-1,3-diols 9a,b and triaminopropane 16f with IC50-
values between 8.5 and 13.6 μM.
From a structure–activity relationship viewpoint, the presence
of a chlorinated aromatic ring seems to contribute to the
antiplasmodial activity of these functionalized aminopropanes,
and the introduction of a dimethylamino group at the expense of
a diethylamino moiety might provide better activities in some
cases. It is noteworthy that these compounds were synthesized
in racemic form, and it is conceivable that enantiomerically
pure variants could deliver superior activities. It should also be
noted that, in general, the bioactivities reported in this paper are
less pronounced as compared to those described in literature
precedents on the synthesis and evaluation of functionalized
aminopropanes [6,8].
Conclusion
In summary, a variety of 2-amino-3-arylpropan-1-ols, anti-2-
amino-3-aryl-3-methoxypropan-1-ols and anti-2-amino-1-aryl-
propan-1,3-diols were prepared selectively through elaboration
of trans-4-aryl-3-chloro-β-lactams. Furthermore, a number of
2-(azidomethyl)aziridines were converted into novel 2-[(1,2,3-
triazol-1-yl)methyl]aziridines by Cu(I)-catalyzed azide-alkyne
cycloaddition, followed by microwave-assisted, regioselective
ring opening by diethyl- or dimethylamine towards the corre-
sponding 1-(2,3-diaminopropyl)-1,2,3-triazoles. From a syn-
thetic viewpoint, new insights were provided concerning the
water-induced ring opening of nonactivated cis- and trans-2-
aryl-3-(hydroxymethyl)aziridines and with respect to the syn-
thesis and use of 1-arylmethyl-2-(azidomethyl)aziridines for
azide-alkyne cycloaddition reactions. From a biological view-
point, most of these compounds exhibited weak antiplasmodial
activity, although six representatives showed moderate antiplas-
modial activity against both a chloroquine-sensitive and a
chloroquine-resistant strain of P. falciparum with IC50-values
of ≤25 μM.
Experimental
General information regarding NMR, IR, MS and elemental
analyses, melting point measurements, and microwave reaction
conditions can be found in the literature [8].
anti-2-(N-Benzylamino)-1-(4-chlorophenyl)-
propan-1,3-diol (9a)
Recrystallization from hexane/EtOAc (1:25), white crystals,
95%. Mp 192.3 °C; 1H NMR (300 MHz, CDCl3) δ 2.39 (s, 2H),
3.12–3.18 (m, 1H), 3.54 (dd, J = 13.0, 3.6 Hz, 1H), 3.82 (dd,
J = 13.0, 5.8 Hz, 1H), 4.27 and 4.32 (2 d, J = 13.2 Hz, 2 × 1H),
5.24 (d, J = 2.2 Hz, 1H), 7.04–7.07, 7.19–7.36, 7.46–7.49 and
7.69–7.71 (4 m, 2H, 3H, 2H, 2H); 13C NMR (75 MHz, CDCl3)
δ 51.0, 59.4, 62.6, 72.0, 127.2, 128.1, 128.7, 128.8, 128.9,
133.4, 137.0, 139.1; IR (cm−1) νmax: 3437 (OH), 3342 (NH),
2926, 1448, 1162, 1008, 681; MS (70 eV) m/z (%): 292/4
(M+ + 1, 100); HRMS (ESI): [M + H]+ calcd for C16H19ClNO2,
292.1104; found, 292.1112.
syn-2-(N-tert-Butylamino)-1-(2-methoxyphen-
yl)propan-1,3-diol (12a)
Rf 0.07 (EtOAc), white crystals, 30%. Mp 112.8 °C; 1H NMR
(300 MHz, CDCl3) δ 1.03 (s, 9H), 2.77 (ddd, J = 7.1, 3.0,
3.0 Hz, 1H), 3.50–3.51 (m, 2H), 3.86 (s, 3H), 4.80 (d, J =
7.1 Hz, 1H), 6.87–6.89, 6.98–7.03, 7.22–7.28 and 7.47–7.50
(4 m, 4 × 1H); 13C NMR (75 MHz, CDCl3) δ 30.0, 50.8, 55.6,
58.1, 63.7, 68.5, 110.4, 121.3, 127.7, 128.4, 130.5, 156.5; IR
(cm−1) νmax: 3391 (NH), 3313 (OH), 3058, 3004, 2987, 2957,
2927, 2873, 2838, 1492, 1467, 1438, 1368, 1242, 1066, 1050,
1027, 755; MS (70 eV) m/z (%): 254 (M+ + 1, 100); HRMS
(ESI): [M + H]+calcd for C14H24NO3, 254.1756; found,
254.1766.
2-Azidomethyl-1-(phenylmethyl)aziridine
(14a)
Rf 0.20 (hexane/EtOAc 4:1), yellow oil, 70%. 1H NMR
(300 MHz, CDCl3) δ 1.51 (d, J = 6.1 Hz, 1H), 1.79 (d, J =
3.3 Hz, 1H), 1.79–1.86 (m, 1H), 3.18 and 3.27 (2 dd, J = 12.9,
6.6, 4.4 Hz, 2H) 3.38 and 3.58 (2 d, J = 13.2 Hz, 2H), 7.24–7.36
(m, 5H); 13C NMR (75 MHz, CDCl3) δ 32.2, 37.9, 53.8, 64.3,
127.4, 128.3, 128.6, 138.8; IR (cm−1) νmax: 2088 (N3), 1453,
1357, 1322, 1255, 1159, 1062, 1028, 907, 732, 697; MS
(70 eV) m/z (%): 189 (M+ + 1, 100); HRMS (ESI): [M + H]+
calcd for C10H13N4, 189.1140; found, 189.1141.
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1-Phenylmethyl-2-[(4-phenyl-1,2,3-triazol-1-
yl)methyl]aziridine (15a)
Rf 0.23 (CHCl3/MeOH 98:2), viscous light-brown oil, 61%.
1H NMR (300 MHz, CDCl3) δ 1.65 (d, J = 6.6 Hz, 1H), 1.88 (d,
J = 3.3 Hz, 1H), 2.01–2.08 (m, 1H), 3.09 and 3.67 (2 d, J =
12.9 Hz, 2H), 3.93 and 4.70 (2 dd, J = 14.3, 8.2, 3.3 Hz, 2H),
7.06–7.43 (m, 8H), 7.49 (s, 1H), 7.66–7.69 (m, 2H); 13C NMR
(75 MHz, CDCl3) δ 32.4, 38.3, 53.5, 64.5, 119.9, 125.9, 127.7,
128.1, 128.4, 128.6, 128.7, 130.8, 138.2, 147.9; IR (cm−1) νmax:
2919, 1453, 1358, 1225, 1075, 1046, 1027, 763, 731, 694; MS
(70 eV) m/z (%): 291 (M+ + 1, 100); HRMS (ESI): [M + H]+
calcd for C18H19N4, 291.1610; found, 291.1613.
3-Diethylamino-2-(phenylmethyl)amino-1-(4-
phenyl-1,2,3-triazol-1-yl)propane (16a)
Rf 0.19 (CHCl3/MeOH 97:3), light-brown oil, 56%. 1H NMR
(300 MHz, CDCl3) δ 0.92 (t, J = 7.2 Hz, 6H), 2.26–2.52 (m,
6H), 3.05–3.13 (m, 1H), 3.74 and 3.81 (2 d, J = 13.5 Hz, 2H),
4.36 and 4.44 (2 dd, J = 14.2, 4.9, 4.7 Hz, 2H), 7.21–7.44 and
7.82–7.84 (2 m, 10H), 7.86 (s, 1H); 13C NMR (75 MHz,
CDCl3) δ 11.8, 47.1, 52.0, 52.3, 55.0, 55.4, 121.2, 125.8, 127.2,
128.1, 128.2, 128.6, 128.9, 130.9, 140.2, 147.5; IR (cm−1) νmax:
2967, 1462, 1454, 1073, 762, 734, 694; MS (70 eV) m/z (%):
364 (M+ + 1, 100); HRMS (ESI): [M + H]+ calcd for
C22H30N5, 364.2501; found, 364.2503.
Supporting Information
Supporting Information File 1
Experimental procedures and characterization data.
[http://www.beilstein-journals.org/bjoc/content/
supplementary/1860-5397-7-205-S1.pdf]
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